Lead Sponsor

Korean Breast Cancer Study Group

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•1. Patients with advanced breast cancer with radiographic confirmation of bone metastases (minimum of one bone scan lesion must be confirmed as metastatic on plain radiographs or CT/MR imaging)
•2. Men or women aged ≥ 18 years
•3. WHO (ECOG) performance status 0-2
•4. Women of child-bearing potential must be using a reliable and appropriate method of contraception
•5. Urine sample taken and sent to the central laboratory for baseline Ntx analysis
•6. Written informed consent.

•1. Bisphosphonate treatment within the 4 weeks prior to planned first study treatment
•2. Abnormal renal function as evidenced by a calculated creatinine clearance \< 30 ml/minute
•3. Poor venous access
•4. Metabolic bone disease
•5. Unable to comply with study procedures, especially the reliable collection of urine samples for bone resorption marker measurements
•6. Estimated life expectancy of \< 6 months
•7. Treatment with systemic bone seeking radioisotopes within the 3 months prior to study entry
•8. Wide field (hemi-body) radiotherapy within the 3 months prior to study entry
•9. Concomitant medication with drugs known to affect bone metabolism
•10. Pregnancy or breast-feeding
•11. Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular), or a current or prior diagnosis of osteonecrosis of the jaw (ONJ)
•12. Recent (within 4 weeks of study entry\*) or planned dental or jaw surgery

Related studies

NCT06994377 · Metastatic Breast Cancer

NCT07222215 · Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, and more

NCT02422641 · Metastatic Breast Cancer, Leptomeningeal Disease

NCT06110793 · Metastatic Breast Cancer

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more

Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients